ToothWave Plaque and Gingivitis Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03885323 |
Recruitment Status :
Completed
First Posted : March 21, 2019
Last Update Posted : November 25, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gingivitis Plaque Calculus, Dental | Device: RF utilizing powered toothbrush Device: Control placebo with no RF | Not Applicable |
This is a single blind, prospective study aimed to evaluate the safety and efficacy of the Silk'n toothbrush in reduction of gingivitis, dental plaque and calculus.
The study includes 84 treatment sessions, twice a day, and 4 clinic visits over a period of 6 weeks.
One treatment group (Silk'n toothbrush - ToothWave) and 1 control group (an ADA approved power toothbrush (PTB)) will participate in the study.
For each patient, assessment data will be collected at baseline, 4 weeks, and at 6 weeks. The average data sets will be calculated for each group.
Treatment is defined as a timed 2 minutes of teeth brushing in a regular man-ner, twice a day (morning and evening). Brushing will be undertaken using the Silk'n toothbrush and standard fluoride toothpaste. The control group will use a regular PTB and standard fluoride toothpaste.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 86 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Single blind prospective study |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | Participants will not know if the toothbrush is a treatment or control brush. Outcome assessor will be blinded as well and will not know which product was dispensed to which participant. |
Primary Purpose: | Treatment |
Official Title: | Safety and Efficacy of the Silk'n Toothbrush (ToothWave) Home Use Device for Reduction of Gingivitis, Dental Plaque and Calculus |
Actual Study Start Date : | February 28, 2019 |
Actual Primary Completion Date : | April 15, 2019 |
Actual Study Completion Date : | April 15, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment group
The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
|
Device: RF utilizing powered toothbrush
RF utilizing Powered toothbrush
Other Name: RF toothbrush |
Placebo Comparator: Control group
Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
|
Device: Control placebo with no RF
Placebo control, with no RF |
- Dental plaque [ Time Frame: 6 weeks ]A reduction in the level of dental plaque according to Rustogi Modification of the Navy Plaque Index (RMNPI).
- Gingival inflammation [ Time Frame: 6 weeks ]A reduction in the level of gingival inflammation according to the Modified Gingival Index (MGI).
- Calculus [ Time Frame: 6 weeks ]A reduction of calculus deposits as evaluated by Volpe-Manhold Index

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult subjects aged 18-70, that are in good health.
-
Subject must have:
2.2. Baseline gingivitis (MGI) score of at least 1.80, 2.3. Dental Plaque mean score greater than 0.6 according to the RMNPI Index. 2.4. Total Calculus deposits greater than 7 according to the Volpe-Manhold Index.
- Have a minimum of 20 'scorable' teeth (excluding 3rd molars).
- The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects. Subjects will sign the Informed Consent Form.
- The subjects should be willing to comply with the study procedure and schedule, including the follow up visits.
Exclusion Criteria:
- Current or history of oral cavity cancer or oropharyngeal cancer.
- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
- Pregnant or nursing by subject report.
- Any active condition in the oral cavity at the discretion of the investigator.
- Any surgery in the oral cavity within 3 months prior to treatment, or before complete healing.
- Subjects that do not brush regularly.
- Any condition that might make it unsafe for the subject to participate in this study, at the discretion of the investigator.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03885323
United States, Indiana | |
Salus research | |
Fort Wayne, Indiana, United States, 46825 |
Principal Investigator: | Jeffry L. Milleman, DDS, MPA | Salus Research |
Responsible Party: | Home Skinovations Ltd. |
ClinicalTrials.gov Identifier: | NCT03885323 |
Other Study ID Numbers: |
DO116217A |
First Posted: | March 21, 2019 Key Record Dates |
Last Update Posted: | November 25, 2020 |
Last Verified: | February 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Gingivitis Dental Calculus Calculi Gingival Diseases Periodontal Diseases |
Mouth Diseases Stomatognathic Diseases Pathological Conditions, Anatomical Dental Deposits Tooth Diseases |